503b bulk drug list exclusion

FDA to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list — Photo by Leeloo The First on Pexels

30% Cost Hit Hospitals With FDA's Semaglutide Exclusion

A 30% cost hit is projected for hospitals after the FDA’s exclusion of semaglutide and related GLP-1s. No, this exclusion makes adding these blockbuster weight-loss drugs to a hospital compounding line far from easy. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice.